Cobenfy is tanking as a schizophrenia drug, so hey, let’s rebrand it for Alzheimer’s.

https://www.cnbc.com/2025/01/15/bristol-myers-squibb-schizophrenia-drug-cobenfy-could-treat-alzheimers.html

This drug was all the talk of healthcare last spring/summer. Bristol Myers Squibb, or BMS, unloaded the Brinks truck to hire the best talent they could hire as pharma reps to push this new and improved schizophrenia med out to everyone. Remember our little discussion about Schizophrenia approval opens the door for bipolar and depression treatment approval down the road? Well Cobenfy has a different game plan.

But first, it should be noted that myself and a few colleagues call this drug Cobenfail. Because it makes people SO SICK. Like poop your pants suddenly diarrhea, vomiting, nausea. Most patients cannot tolerate much more than a week on it and wave the white flag wanting to go off it. It is not selling like it should. So it should be NO surprise they are immediately going for a new FDA indication: Alzheimer’s. Which in this article, they WILLINGLY ADMIT is is the target audience with the “most patients” that could be prescribed it.

So now we are going to have cognitively altered and confused Alzheimer’s patients pooping their pants and vomiting everywhere. Sounds like a really horrible plan.